OPTINOSE INC. - COMMON STOCK

Optinose to Present at the Needham Virtual Healthcare Conference

04 4 2024 16:01:00 提供 Nasdaq GlobeNewswire

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

15 3 2024 15:34:50 提供 Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

07 3 2024 07:00:43 提供 Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

29 2 2024 16:40:00 提供 Nasdaq GlobeNewswire

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

18 1 2024 12:00:00 提供 Nasdaq GlobeNewswire

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

06 12 2023 07:00:00 提供 Nasdaq GlobeNewswire

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

22 11 2023 09:00:00 提供 Nasdaq GlobeNewswire

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

09 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Third Quarter 2023 Financial Results

27 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

Optinose to Present at the 2023 Cantor Global Healthcare Conference

22 9 2023 09:01:00 提供 Nasdaq GlobeNewswire

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

10 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

27 7 2023 07:00:01 提供 Nasdaq GlobeNewswire

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

16 6 2023 16:08:00 提供 Nasdaq GlobeNewswire

Optinose to Present at the Jefferies Healthcare Conference

02 6 2023 13:00:00 提供 Nasdaq GlobeNewswire

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

11 5 2023 07:00:18 提供 Nasdaq GlobeNewswire

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

04 5 2023 07:00:01 提供 Nasdaq GlobeNewswire

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

01 5 2023 16:30:00 提供 Nasdaq GlobeNewswire

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 4 2023 08:00:01 提供 Nasdaq GlobeNewswire

Optinose to Present at the Needham Virtual Healthcare Conference

12 4 2023 16:00:00 提供 Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

07 3 2023 07:00:56 提供 Nasdaq GlobeNewswire